Nebulized Budesonide in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Objective:To evaluate the clinical efficacy of nebulized budesonide (NB) in acute exacerbations of chronic obstructive pulmonary disease (COPD).Methods:Patients were randomly divided into three groups.The NS group received nebulized budesonide by exacerbation with 2mg every 8h.The prednisolone group was treated with 40mg by intravenous every day.The placebo was offered common treatment and not treated with adrenocortical hormones.All groups were observed for 48h and 7d.Results:Both budesonide and prednisolone improved in FEV1、PaO2 and PaCO2 wwhen compared with placebo(P0.05).The difference in FEV1、PaO2、 PaCO2 between budesonide and prednisolone was not significant(P0.05).The occurrence of serious adverse in the NS group were lower than the PS group(P0.05).Conclusion:Both budesonide and prednisolone improved obstruent airflow in COPD patients Nebulized budesonide may be an alternative to intravenous prednisolone in the treatment of nonacidotic exacerbations of COPD with lower adverse events.